Alexis Borisy has launched a company that plans to combine multiple drug compounds to create precise, durable cancer treatments. STAT+: Alexis Borisy, biotech's 'man of many hats,' dons another By Allison DeAngelis Courtesy IDRx On Tuesday, Borisy launched a company called IDRx that plans to combine multiple drug compounds to create precise, durable cancer treatments. Read More Opinion: Fast science can be good science, even more so when lives are at stake By Ron Peck Adobe Fast science relies on partnerships that combine innovative technologies and clinical trial models bolstered by better regulatory procedures. Read More STAT+: Genomics is racing toward a $100 genome. Are we ready for it? By Jonathan Wosen Adobe Interpreting DNA data, counseling patients, and proceeding ethically will pose challenges as whole genome sequencing takes off, experts say. Read More Sponsor content by STAT Events STAT Event: Creating AI That Improves Health On August 3, hear how researchers aim to create a "data economy" to ensure that artificial intelligence lives up to its promise. Register now to join. Opinion: A better understanding of human diversity is needed to equitably advance precision medicine By David Reese and Kári Stefánsson Adobe Increasing genetic diversity in global databases and biobanks is essential to advancing the field of precision medicine. Read More STAT+: Major European research funders often fail to set policies or monitor progress on clinical trial transparency By Ed Silverman Adobe Organizations that fund medical research in Europe often fail to monitor progress on clinical trial registration and publication. Read More Tuesday, August 2, 2022 1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser
No comments